Nuclear Is the Energy Story of 2026. Here Are 3 Stocks to Own All Year.

The article is constructive on the nuclear power theme, citing IEA estimates that global nuclear capacity could rise more than 50% from 2025 to 2050. It highlights Cameco's recovery as uranium reached $84.18/lb, BWX's expanding government/commercial backlog, and Oklo's high-growth but pre-revenue microreactor opportunity with first Idaho reactors expected in 2027. The piece is broadly positive for the group, though it is more thematic commentary than a near-term catalyst.

Analysis

The cleanest read-through is not “nuclear is back,” but that the value chain is bifurcating: upstream fuel and regulated components should monetize earlier than new-build reactor IP. CCJ and BWXT have visible cash-flow conversion because supply remains structurally tight and qualification barriers are high; OKLO is still a financing instrument on future optionality, not an operating story. That makes BWXT the higher-quality duration exposure: it participates in defense spending, fuel handling, and advanced reactor components, so it is less hostage to any single policy cycle than either pure uranium leverage or pre-revenue reactor hype.

The second-order winner is the industrial base around nuclear qualification, not the headline operators. If AI/data-center power demand keeps forcing utilities and hyperscalers to seek firm low-carbon baseload, the bottleneck shifts to licensed fuel fabrication, HALEU handling, reactor components, and engineering services — areas where supply is thin and pricing power can expand faster than unit volumes. That also raises the odds that established vendors with government relationships take share from smaller entrants that can win press releases but not permits, fuel access, or delivery schedules.

The main contrarian risk is valuation compression long before any fundamental disappointment. CCJ and BWXT are already discounting a multi-year capital cycle, so any delay in permitting, fuel availability, or project execution can produce a sharp rerating even if the secular thesis remains intact. OKLO carries the most binary path dependency: if first commercial deployments slip beyond the current window, the stock can de-rate violently because the market is paying for a timeline, not current earnings.

The consensus may be underestimating how much of the upside is already in the equities, while still underpricing the duration of the theme. Nuclear often trades well on narrative until one of three things breaks it: regulatory delay, cost inflation in specialized components, or a broader risk-off move that cuts off speculative capital. In that sense, the best opportunities may be relative-value expressions rather than outright beta to the theme.

Key Decisions for Investors

• Long BWXT vs short OKLO for the next 6-12 months: favor the cash-generative, contract-backed operator over the pre-revenue optionality vehicle; target a modest absolute gain on BWXT while limiting factor risk through the hedge.
• Buy CCJ on pullbacks rather than strength; use a 3-6 month window and treat it as a uranium price lever, but keep sizing smaller than BWXT because earnings sensitivity cuts both ways if spot uranium stalls.
• Own BWXT calls or call spreads dated 9-12 months out to capture backlog re-rating, with risk defined to premium; this is the cleanest way to express the “regulated bottleneck” thesis without overcommitting capital.
• Avoid chasing OKLO into momentum unless there is concrete evidence of schedule de-risking; if you want exposure, use a small starter position or defined-risk calls only, because any delay can produce a large drawdown.
• Pair long CCJ/BWXT against a basket of over-owned secular growth names if you want a thematic rotation trade; the catalyst is multiple expansion from hard-asset scarcity, but the stop should be any sign of project delay or commodity price reversal.